Q-omics provides the consensus-scored MIR548AY profile across patient tissues and cancer cell-line models. MIR548AY expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR548AY is differentially expressed in 3, with the highest sampling consensus in LIHC. Additionally, MIR548AY RNA expression shows 5,518 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, LIHC, and STAD as cancer lineages where MIR548AY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548AY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548AY survival associations across molecular data types. MIR548AY RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548AY RNA expression–survival associations across cancer types. High MIR548AY expression shows unfavorable associations in MESO, BRCA, UVM, ESCA, COAD and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR548AY RNA expression.
This table summarizes MIR548AY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548AY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548AY shows lower tumor expression in LUSC and higher tumor expression in LIHC and LUAD. The LIHC box plot shows higher MIR548AY RNA expression in tumor versus normal tissue (log2 FC = +0.171, t-test p = .030).
This table shows molecular features associated with MIR548AY in patient tissues and cancer cell lines. In patient samples, MIR548AY shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
